CCR9 and inflammatory bowel disease.
BACKGROUND
The pathological features of inflammatory bowel disease (IBD) are associated with leukocyte cell infiltrates, which contribute to disease progression and persistence by production of proinflammatory mediators. Recruiting leukocytes to the gut involves local expression of chemokines that interact with receptors on the leukocytes' surface. Specific antagonists may interfere with leukocyte recruitment to the intestine. The chemokine receptor CCR9 is one of the key molecules in leukocyte homing to gut mucosa. CCR9 antagonists have been shown to retard progression in patients with IBD.


OBJECTIVE
To discuss CCR9 as a potential target for the treatment of IBD.


METHODS
A literature review.


CONCLUSIONS
The therapeutic effects of CCR9 antagonists, in combination with established therapies, should be evaluated in an attempt to slow down leukocyte recruitment at early stages of IBD.
Koenecke
Christian
C
Institute of Immunology, Hannover Medical School, Carl-Neuberg-Str.1, D-30625 Hannover, Germany.
Förster
Reinhold
R
D000818:Animals; D004195:Disease Models, Animal; D018450:Disease Progression; D016503:Drug Delivery Systems; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000503:physiopathology; D007962:Leukocytes / Q000378:metabolism; D054388:Receptors, CCR / Q000037:antagonists & inhibitors*
C119309:CC chemokine receptor 9; D018836:Inflammation Mediators; D054388:Receptors, CCR